CLINICAL CHARACTERISTICS OF PATIENTS WITH MULTIPLEMYELOMA. PRELIMINARY RESULTS OF A PROSPECTIVEMULTICENTER REGISTRY OF THE COMUNIDAD VALENCIANA(SPAIN).
(Abstract release date: 05/19/16)
EHA Library. DE LA RUBIA J. 06/09/16; 134856; PB1956
Prof. Dr. Javier DE LA RUBIA
Contributions
Contributions
Abstract
Abstract: PB1956
Type: Publication Only
Background
Multiple myeloma (MM) is the second most common malignant B-cell disorder. It accounts for 1% of all malignant diseases and for slightly more than 10% of all hematological malignancies. Based on international data, the incidence of MM in Spain has been estimated to be 0.056/1000 of population. However, most of this information is collected from secondary sources as press releases, industry, associations, analyst reports and others but real life epidemiological data based on national or local registries is lacking.
Aims
In order to have a better knowledge of the clinical characteristics at diagnosis of MM patients and to know the real incidence and prevalence of patients with newly diagnosed MM in our environment, the Grupo de Estudios de Mieloma (GREMI) developed in 2013 a prospective, multicenter registry including every patient undergoing a first diagnosis of MM in every public or private sanitary center of the Comunidad Valenciana, Spain.
Methods
The CV involves three regions in Spain (Alicante, Castellón, and Valencia) with a global population of 5,034,665 habitants. A total of 2,578,719 people live in Valencia, 1,868,438 in Alicante and 587,508 in Castellón. Diagnosis of MM is done according to the International Myeloma Working Group criteria. Primary data collection for the registry is done in every center by the local investigators. Immediately after a new diagnosis of MM is performed, the patient is registered on-line by means of an electronic database. Clinical and epidemiological data at presentation, the type of therapy administered, and survival status are included. We present the preliminary epidemiological, clinical, and laboratory results of the patients included in the registry in the period 2013-2014.
Results
From January 2013 to December 2014, a total of 332 patients have been registered in 23 centers. The overall incidence of patients with newly diagnosed MM (NDMM) in the Comunidad Valenciana in the study period was 0.066/1000 of population (0.046 in Alicante, 0.082 in Castellón, and 0.077 in Valencia). Three hundred and twenty-seven (98.5%) patients were of Caucasian descent. Median (range) age of the series was 70.76 (43.07-92.15) years and 95 (28.61%) of the patients were younger than 65 years. One hundred and seventy-seven (53.3%) patients were male. Overall, IgG myeloma was the most commonly observed type of myeloma (174 patients, 52.4%). Eighty-eight (26.5%), 52 (15.7%), and 82 (24.7%) patients presented with an International Staging System of I, II, and III, respectively. Clinical and laboratory data at time of diagnosis are shown in the Table.
Conclusion
This is the first epidemiological registry for NDMM patients available in Spain. Our preliminary results indicate that the incidence of MM in the Comunidad Valenciana is similar to that generally reported. Cytogenetic data were routinely collected in the great majority of patients 248 (74.7%). Survival data during the study period will be presented.
Session topic: E-poster
Keyword(s): Clinical data, Epidemiology, Multiple myeloma
Type: Publication Only
Background
Multiple myeloma (MM) is the second most common malignant B-cell disorder. It accounts for 1% of all malignant diseases and for slightly more than 10% of all hematological malignancies. Based on international data, the incidence of MM in Spain has been estimated to be 0.056/1000 of population. However, most of this information is collected from secondary sources as press releases, industry, associations, analyst reports and others but real life epidemiological data based on national or local registries is lacking.
Aims
In order to have a better knowledge of the clinical characteristics at diagnosis of MM patients and to know the real incidence and prevalence of patients with newly diagnosed MM in our environment, the Grupo de Estudios de Mieloma (GREMI) developed in 2013 a prospective, multicenter registry including every patient undergoing a first diagnosis of MM in every public or private sanitary center of the Comunidad Valenciana, Spain.
Methods
The CV involves three regions in Spain (Alicante, Castellón, and Valencia) with a global population of 5,034,665 habitants. A total of 2,578,719 people live in Valencia, 1,868,438 in Alicante and 587,508 in Castellón. Diagnosis of MM is done according to the International Myeloma Working Group criteria. Primary data collection for the registry is done in every center by the local investigators. Immediately after a new diagnosis of MM is performed, the patient is registered on-line by means of an electronic database. Clinical and epidemiological data at presentation, the type of therapy administered, and survival status are included. We present the preliminary epidemiological, clinical, and laboratory results of the patients included in the registry in the period 2013-2014.
Results
From January 2013 to December 2014, a total of 332 patients have been registered in 23 centers. The overall incidence of patients with newly diagnosed MM (NDMM) in the Comunidad Valenciana in the study period was 0.066/1000 of population (0.046 in Alicante, 0.082 in Castellón, and 0.077 in Valencia). Three hundred and twenty-seven (98.5%) patients were of Caucasian descent. Median (range) age of the series was 70.76 (43.07-92.15) years and 95 (28.61%) of the patients were younger than 65 years. One hundred and seventy-seven (53.3%) patients were male. Overall, IgG myeloma was the most commonly observed type of myeloma (174 patients, 52.4%). Eighty-eight (26.5%), 52 (15.7%), and 82 (24.7%) patients presented with an International Staging System of I, II, and III, respectively. Clinical and laboratory data at time of diagnosis are shown in the Table.
Conclusion
This is the first epidemiological registry for NDMM patients available in Spain. Our preliminary results indicate that the incidence of MM in the Comunidad Valenciana is similar to that generally reported. Cytogenetic data were routinely collected in the great majority of patients 248 (74.7%). Survival data during the study period will be presented.
Session topic: E-poster
Keyword(s): Clinical data, Epidemiology, Multiple myeloma
Abstract: PB1956
Type: Publication Only
Background
Multiple myeloma (MM) is the second most common malignant B-cell disorder. It accounts for 1% of all malignant diseases and for slightly more than 10% of all hematological malignancies. Based on international data, the incidence of MM in Spain has been estimated to be 0.056/1000 of population. However, most of this information is collected from secondary sources as press releases, industry, associations, analyst reports and others but real life epidemiological data based on national or local registries is lacking.
Aims
In order to have a better knowledge of the clinical characteristics at diagnosis of MM patients and to know the real incidence and prevalence of patients with newly diagnosed MM in our environment, the Grupo de Estudios de Mieloma (GREMI) developed in 2013 a prospective, multicenter registry including every patient undergoing a first diagnosis of MM in every public or private sanitary center of the Comunidad Valenciana, Spain.
Methods
The CV involves three regions in Spain (Alicante, Castellón, and Valencia) with a global population of 5,034,665 habitants. A total of 2,578,719 people live in Valencia, 1,868,438 in Alicante and 587,508 in Castellón. Diagnosis of MM is done according to the International Myeloma Working Group criteria. Primary data collection for the registry is done in every center by the local investigators. Immediately after a new diagnosis of MM is performed, the patient is registered on-line by means of an electronic database. Clinical and epidemiological data at presentation, the type of therapy administered, and survival status are included. We present the preliminary epidemiological, clinical, and laboratory results of the patients included in the registry in the period 2013-2014.
Results
From January 2013 to December 2014, a total of 332 patients have been registered in 23 centers. The overall incidence of patients with newly diagnosed MM (NDMM) in the Comunidad Valenciana in the study period was 0.066/1000 of population (0.046 in Alicante, 0.082 in Castellón, and 0.077 in Valencia). Three hundred and twenty-seven (98.5%) patients were of Caucasian descent. Median (range) age of the series was 70.76 (43.07-92.15) years and 95 (28.61%) of the patients were younger than 65 years. One hundred and seventy-seven (53.3%) patients were male. Overall, IgG myeloma was the most commonly observed type of myeloma (174 patients, 52.4%). Eighty-eight (26.5%), 52 (15.7%), and 82 (24.7%) patients presented with an International Staging System of I, II, and III, respectively. Clinical and laboratory data at time of diagnosis are shown in the Table.
Conclusion
This is the first epidemiological registry for NDMM patients available in Spain. Our preliminary results indicate that the incidence of MM in the Comunidad Valenciana is similar to that generally reported. Cytogenetic data were routinely collected in the great majority of patients 248 (74.7%). Survival data during the study period will be presented.
Session topic: E-poster
Keyword(s): Clinical data, Epidemiology, Multiple myeloma
Type: Publication Only
Background
Multiple myeloma (MM) is the second most common malignant B-cell disorder. It accounts for 1% of all malignant diseases and for slightly more than 10% of all hematological malignancies. Based on international data, the incidence of MM in Spain has been estimated to be 0.056/1000 of population. However, most of this information is collected from secondary sources as press releases, industry, associations, analyst reports and others but real life epidemiological data based on national or local registries is lacking.
Aims
In order to have a better knowledge of the clinical characteristics at diagnosis of MM patients and to know the real incidence and prevalence of patients with newly diagnosed MM in our environment, the Grupo de Estudios de Mieloma (GREMI) developed in 2013 a prospective, multicenter registry including every patient undergoing a first diagnosis of MM in every public or private sanitary center of the Comunidad Valenciana, Spain.
Methods
The CV involves three regions in Spain (Alicante, Castellón, and Valencia) with a global population of 5,034,665 habitants. A total of 2,578,719 people live in Valencia, 1,868,438 in Alicante and 587,508 in Castellón. Diagnosis of MM is done according to the International Myeloma Working Group criteria. Primary data collection for the registry is done in every center by the local investigators. Immediately after a new diagnosis of MM is performed, the patient is registered on-line by means of an electronic database. Clinical and epidemiological data at presentation, the type of therapy administered, and survival status are included. We present the preliminary epidemiological, clinical, and laboratory results of the patients included in the registry in the period 2013-2014.
Results
From January 2013 to December 2014, a total of 332 patients have been registered in 23 centers. The overall incidence of patients with newly diagnosed MM (NDMM) in the Comunidad Valenciana in the study period was 0.066/1000 of population (0.046 in Alicante, 0.082 in Castellón, and 0.077 in Valencia). Three hundred and twenty-seven (98.5%) patients were of Caucasian descent. Median (range) age of the series was 70.76 (43.07-92.15) years and 95 (28.61%) of the patients were younger than 65 years. One hundred and seventy-seven (53.3%) patients were male. Overall, IgG myeloma was the most commonly observed type of myeloma (174 patients, 52.4%). Eighty-eight (26.5%), 52 (15.7%), and 82 (24.7%) patients presented with an International Staging System of I, II, and III, respectively. Clinical and laboratory data at time of diagnosis are shown in the Table.
Conclusion
This is the first epidemiological registry for NDMM patients available in Spain. Our preliminary results indicate that the incidence of MM in the Comunidad Valenciana is similar to that generally reported. Cytogenetic data were routinely collected in the great majority of patients 248 (74.7%). Survival data during the study period will be presented.
Session topic: E-poster
Keyword(s): Clinical data, Epidemiology, Multiple myeloma
{{ help_message }}
{{filter}}